Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 531Gastro-enteropancreatic neuroendocrine tumor 58Carcinoid Tumor 58Neoplasms 49Carcinoma, Neuroendocrine 44Pancreatic Neoplasms 36Adenoma, Islet Cell 33Neoplasm Metastasis 28Pheochromocytoma 25Colorectal Neoplasms 24Paraganglioma 23Stomach Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Lung Neoplasms 20Carcinoma, Hepatocellular 20Sarcoma 19Carcinoma 19Thyroid Neoplasms 18Gastrointestinal Neoplasms 18Neuroblastoma 15Cholangiocarcinoma 14Carcinoma, Renal Cell 14Small Cell Lung Carcinoma 13Melanoma 13Esophageal Neoplasms 13Serotonin Syndrome 12Colonic Neoplasms 12Brain Neoplasms 11Adenocarcinoma 11

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extrapancreatic Neuroendocrine Tumor × NET × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡